BlackRock’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-5,631,488
| Closed | -$54.1M | – | 5574 |
|
|
2024
Q4 | $54.1M | Buy |
5,631,488
+507,519
| +10% | +$2.65M | ﹤0.01% | 2408 |
|
|
2024
Q3 | $14.7M | Buy |
5,123,969
+218,809
| +4% | +$677K | ﹤0.01% | 3216 |
|
|
2024
Q2 | $14.3M | Sell |
4,905,160
-44,910
| -0.9% | -$123K | ﹤0.01% | 3169 |
|
|
2024
Q1 | $15.8M | Sell |
4,950,070
-81,103
| -2% | -$270K | ﹤0.01% | 3123 |
|
|
2023
Q4 | $16.9M | Sell |
5,031,173
-21,806
| -0.4% | -$56.2K | ﹤0.01% | 3105 |
|
|
2023
Q3 | $12M | Sell |
5,052,979
-131,286
| -3% | -$275K | ﹤0.01% | 3226 |
|
|
2023
Q2 | $9.12M | Buy |
5,184,265
+3,294,442
| +174% | +$8.42M | ﹤0.01% | 3461 |
|
|
2023
Q1 | $5.82M | Buy |
1,889,823
+170,749
| +10% | +$1.02M | ﹤0.01% | 3569 |
|
|
2022
Q4 | $9.11M | Buy |
1,719,074
+271,156
| +19% | +$1.24M | ﹤0.01% | 3442 |
|
|
2022
Q3 | $5.11M | Buy |
1,447,918
+331,185
| +30% | +$1.1M | ﹤0.01% | 3748 |
|
|
2022
Q2 | $2.88M | Sell |
1,116,733
-1,352,221
| -55% | -$3.76M | ﹤0.01% | 4075 |
|
|
2022
Q1 | $11.1M | Sell |
2,468,954
-84,036
| -3% | -$379K | ﹤0.01% | 3523 |
|
|
2021
Q4 | $17.4M | Buy |
2,552,990
+19,851
| +0.8% | +$135K | ﹤0.01% | 3358 |
|
|
2021
Q3 | $18.5M | Sell |
2,533,139
-8,686
| -0.3% | -$74.5K | ﹤0.01% | 3330 |
|
|
2021
Q2 | $25.5M | Sell |
2,541,825
-284,731
| -10% | -$2.55M | ﹤0.01% | 3150 |
|
|
2021
Q1 | $27M | Buy |
2,826,556
+1,278,113
| +83% | +$12.5M | ﹤0.01% | 3017 |
|
|
2020
Q4 | $17M | Buy |
1,548,443
+593,188
| +62% | +$6.26M | ﹤0.01% | 3094 |
|
|
2020
Q3 | $8.47M | Buy |
+955,255
| New | +$10.9M | ﹤0.01% | 3317 |
|
Other funds holding PSTX
BlackRock's PSTX Position: Q1 2025 in Review
BlackRock sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 5,631,488 shares — an estimated $54.1M sold.
BlackRock first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $54.1M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- BlackRock reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- BlackRock sold 5,631,488 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $54.1M.
- BlackRock first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- BlackRock's Poseida Therapeutics, Inc. Common Stock position peaked at $54.1M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.